Chemours Company Insiders
CC Stock | USD 21.53 0.73 3.51% |
Chemours' insiders are aggressively selling. The analysis of insiders' sentiment of trading Chemours Co stock suggests that all insiders are panicking at this time. Chemours employs about 6.2 K people. The company is managed by 36 executives with a total tenure of roughly 132 years, averaging almost 3.0 years of service per executive, having 172.22 employees per reported executive.
Mark Vergnano CEO President, Chief Executive Officer, Director |
Dawn Farrell Chairman Independent Chairman of the Board |
Chemours' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-07 | Alvenia Scarborough | Disposed 7500 @ 20.64 | View | ||
2024-08-06 | Diane I Picho | Disposed 73 @ 19.04 | View |
Monitoring Chemours' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Chemours |
Chemours' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Chemours' future performance. Based on our forecasts, it is anticipated that Chemours will maintain a workforce of about 8100 employees by December 2024.Chemours Management Team Effectiveness
The company has Return on Asset (ROA) of 0.0397 % which means that for every $100 of assets, it generated a profit of $0.0397. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1102 %, which means that it produced $0.1102 on every 100 dollars invested by current stockholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. The current year's Return On Capital Employed is expected to grow to -0.02. At present, Chemours' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 703.5 M, whereas Total Assets are forecasted to decline to about 7.5 B.As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 140.1 M. In addition to that, Net Income Applicable To Common Shares is expected to decline to about 355.7 M
Chemours Workforce Comparison
Chemours Co is rated below average in number of employees category among its peers. The total workforce of Materials industry is currently estimated at about 251,857. Chemours holds roughly 6,200 in number of employees claiming about 2.46% of all equities under Materials industry.
Chemours Profit Margins
The company has Net Profit Margin (PM) of 0.01 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.1 %, which signifies that for every $100 of sales, it has a net operating income of $0.1.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.26 | 0.2167 |
|
|
Chemours Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chemours insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chemours' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Chemours insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 1.2222 | 11 | 9 | 124,616 | 5,620 |
2024-03-01 | 0.1667 | 3 | 18 | 21,103 | 53,752 |
2023-12-01 | 0.6667 | 4 | 6 | 6,234 | 23,102 |
2023-09-01 | 1.25 | 10 | 8 | 46,271 | 36,191 |
2023-06-01 | 0.7 | 14 | 20 | 77,578 | 117,039 |
2023-03-01 | 2.0 | 52 | 26 | 1,181,362 | 248,824 |
2022-12-01 | 0.25 | 2 | 8 | 1,225 | 48,199 |
2022-06-01 | 0.875 | 21 | 24 | 357,776 | 1,041,114 |
2022-03-01 | 1.45 | 29 | 20 | 586,847 | 56,067 |
2021-12-01 | 0.5 | 7 | 14 | 168,086 | 396,229 |
2021-09-01 | 0.5833 | 14 | 24 | 210,537 | 264,324 |
2021-06-01 | 2.0 | 12 | 6 | 84,289 | 92,694 |
2021-03-01 | 1.3913 | 32 | 23 | 718,907 | 88,590 |
2020-12-01 | 0.7778 | 7 | 9 | 282,214 | 388,035 |
2020-09-01 | 1.5 | 3 | 2 | 4,751 | 5,456 |
2020-06-01 | 12.0 | 12 | 1 | 107,816 | 289.00 |
2020-03-01 | 2.0909 | 23 | 11 | 1,785,590 | 527,189 |
2019-09-01 | 2.25 | 9 | 4 | 68,327 | 15,674 |
2019-06-01 | 2.4286 | 17 | 7 | 197,214 | 203,581 |
2019-03-01 | 1.4667 | 22 | 15 | 1,672,048 | 573,590 |
2018-09-01 | 0.1667 | 1 | 6 | 692.00 | 129,582 |
2018-06-01 | 0.8 | 12 | 15 | 264,547 | 520,190 |
2018-03-01 | 0.5714 | 12 | 21 | 218,147 | 100,765 |
2017-12-01 | 0.5625 | 9 | 16 | 88,761 | 144,463 |
2017-09-01 | 0.6 | 6 | 10 | 68,597 | 97,589 |
2017-06-01 | 1.6 | 16 | 10 | 72,787 | 77,111 |
2017-03-01 | 1.2 | 18 | 15 | 767,188 | 57,114 |
2016-12-01 | 1.0 | 2 | 2 | 1,649 | 18,989 |
2016-06-01 | 2.5 | 15 | 6 | 226,999 | 27,482 |
2016-03-01 | 0.619 | 13 | 21 | 1,168,026 | 53,045 |
2015-12-01 | 2.0 | 4 | 2 | 39,328 | 19,344 |
2015-09-01 | 33.0 | 66 | 2 | 2,883,943 | 116.00 |
2008-12-01 | 3.0 | 3 | 1 | 30,357,248 | 0.00 |
2008-06-01 | 1.9667 | 59 | 30 | 328,306 | 58,229 |
2007-09-01 | 24.0 | 24 | 1 | 300,465 | 0.00 |
2007-06-01 | 1.8571 | 78 | 42 | 94,188 | 48,545 |
2006-12-01 | 3.0 | 33 | 11 | 37,297 | 68,876 |
2006-09-01 | 1.0645 | 33 | 31 | 50,890 | 100,000 |
2006-06-01 | 0.5478 | 86 | 157 | 484,863 | 838,588 |
2006-03-01 | 0.5775 | 41 | 71 | 309,253 | 961,195 |
2005-12-01 | 6.6 | 33 | 5 | 42,188 | 10,417 |
2005-06-01 | 1.4348 | 66 | 46 | 944,550 | 509,897 |
2005-03-01 | 20.0 | 20 | 1 | 102.00 | 95,000 |
2004-12-01 | 4.6667 | 28 | 6 | 57,572 | 57,469 |
2004-06-01 | 1.375 | 33 | 24 | 92,933 | 56,501 |
2004-03-01 | 2.0 | 8 | 4 | 91.97 | 7,882 |
2003-12-01 | 5.0 | 10 | 2 | 32,925 | 32,841 |
2003-09-01 | 0.5385 | 7 | 13 | 83.11 | 301,477 |
Chemours Notable Stakeholders
A Chemours stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Chemours often face trade-offs trying to please all of them. Chemours' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Chemours' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark Vergnano | President, Chief Executive Officer, Director | Profile | |
Dawn Farrell | Independent Chairman of the Board | Profile | |
Richard Brown | Independent Chairman of the Board | Profile | |
Matthew Abbott | Vice President - Digital and Analytics Platforms Leader | Profile | |
David Shelton | Senior Vice President, General Counsel, Secretary | Profile | |
Alisha Bellezza | President - Thermal & Specialized Solutions | Profile | |
Joseph Martinko | President Solutions | Profile | |
Susan Kelliher | Senior Vice President – Human Resources and Health Services | Profile | |
Gerardo Calderon | President Materials | Profile | |
Eugene Snell | President - Titanium Technologies | Profile | |
Sameer Ralhan | Chief Financial Officer, Senior Vice President, Treasurer | Profile | |
Mark Newman | Chief Operating Officer, Senior Vice President | Profile | |
Edwin Sparks | President - Chemical Solutions Business, Titanium Technologies | Profile | |
Erich Parker | Senior Vice President of Corporate Communications and Chief Brand Officer. | Profile | |
Shane Hostetter | Senior CFO | Profile | |
Shane CPA | Senior CFO | Profile | |
Curtis Anastasio | Independent Director | Profile | |
Curtis Crawford | Independent Director | Profile | |
Mary Cranston | Independent Director | Profile | |
Bradley Bell | Independent Director | Profile | |
Erin Kane | Independent Director | Profile | |
Sean Keohane | Independent Director | Profile | |
Kristine Wellman | General VP | Profile | |
Jonathan Lock | Senior Vice President and Chief Development Officer | Profile | |
Amber Wellman | Chief Officer | Profile | |
Denise Dignam | President - Advanced Performance Materials | Profile | |
Aditya Beri | Interim Business | Profile | |
Sheryl Telford | Chief Sustainability Officer | Profile | |
Ron Charles | Senior People | Profile | |
Sandra Rogers | Independent Director | Profile | |
Kurt Bonner | Ma Relations | Profile | |
Guillaume Pepy | Independent Director | Profile | |
Brandon Ontjes | Vice Relations | Profile | |
Camela Wisel | Chief Accounting Officer, Vice President Controller | Profile | |
Brian Shay | Interim Officer | Profile | |
Alvenia Scarborough | Senior Vice President - Corporate Communications and Chief Brand Officer | Profile |
About Chemours Management Performance
The success or failure of an entity such as Chemours often depends on how effective the management is. Chemours management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chemours management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chemours management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.03) | (0.03) | |
Return On Capital Employed | (0.02) | (0.02) | |
Return On Assets | (0.03) | (0.03) | |
Return On Equity | (0.32) | (0.31) |
Please note, the presentation of Chemours' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chemours' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Chemours' management manipulating its earnings.
Chemours Workforce Analysis
Traditionally, organizations such as Chemours use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Chemours within its industry.Chemours Manpower Efficiency
Return on Chemours Manpower
Revenue Per Employee | 972.1K | |
Revenue Per Executive | 167.4M | |
Net Loss Per Employee | 38.4K | |
Net Loss Per Executive | 6.6M | |
Working Capital Per Employee | 217.6K | |
Working Capital Per Executive | 37.5M |
Complementary Tools for Chemours Stock analysis
When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |